Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19) in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias symptomatic Covid-19detailed results AstraZeneca phase 3 US (D8110C00001), 2021 0.24 [0.18; 0.32]
0.24 [0.18 ; 0.32 ] AstraZeneca phase 3 US (D8110C00001), 2021 1 0% NA not evaluable adverse eventsdetailed results Asano, 2022 1.44 [0.71; 2.93]
AstraZeneca phase 3 US (D8110C00001), 2021 1.62 [1.54; 1.71]
1.62 [1.54 ; 1.70 ] Asano, 2022, AstraZeneca phase 3 US (D8110C00001), 2021 2 0% 32,635 NA not evaluable ATE (Myocardial infarction or ischemic stroke)detailed results AstraZeneca phase 3 US (D8110C00001), 2021 0.12 [0.01; 2.77]
0.12 [0.01 ; 2.77 ] AstraZeneca phase 3 US (D8110C00001), 2021 1 0% 32,379 NA not evaluable Guillain-Barré syndrome detailed results AstraZeneca phase 3 US (D8110C00001), 2021 1.00 [0.03; 29.81]
1.00 [0.03 ; 29.81 ] AstraZeneca phase 3 US (D8110C00001), 2021 1 0% 32,379 NA not evaluable intracranial hemorrhage detailed results Asano, 2022 0.33 [0.01; 16.88]
AstraZeneca phase 3 US (D8110C00001), 2021 0.50 [0.01; 25.21]
0.41 [0.03 ; 6.54 ] Asano, 2022, AstraZeneca phase 3 US (D8110C00001), 2021 2 0% 32,635 NA not evaluable ischemic strokedetailed results Asano, 2022 0.33 [0.01; 16.88]
AstraZeneca phase 3 US (D8110C00001), 2021 0.13 [0.01; 2.77]
0.18 [0.02 ; 2.07 ] Asano, 2022, AstraZeneca phase 3 US (D8110C00001), 2021 2 0% 32,635 NA not evaluable Myocardial infarction detailed results Asano, 2022 0.33 [0.01; 16.88]
AstraZeneca phase 3 US (D8110C00001), 2021 0.25 [0.01; 7.46]
0.28 [0.02 ; 3.68 ] Asano, 2022, AstraZeneca phase 3 US (D8110C00001), 2021 2 0% 32,635 NA not evaluable pulmonary embolismdetailed results Asano, 2022 0.33 [0.01; 16.88]
AstraZeneca phase 3 US (D8110C00001), 2021 0.50 [0.01; 25.21]
0.41 [0.03 ; 6.54 ] Asano, 2022, AstraZeneca phase 3 US (D8110C00001), 2021 2 0% 32,635 NA not evaluable serious adverse events (SAE), anydetailed results Asano, 2022 0.16 [0.01; 4.96]
AstraZeneca phase 3 US (D8110C00001), 2021 0.95 [0.68; 1.33]
0.93 [0.61 ; 1.41 ] Asano, 2022, AstraZeneca phase 3 US (D8110C00001), 2021 2 1% 32,635 NA not evaluable Bell's palsydetailed results AstraZeneca phase 3 US (D8110C00001), 2021 1.00 [0.03; 29.81]
1.00 [0.03 ; 29.81 ] AstraZeneca phase 3 US (D8110C00001), 2021 1 0% 32,379 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-11 19:13 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 89
- treatments: 759
- roots T: 290